MiNK Therapeutics (INKT) officer Form 3 shows 40 common shares held

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. filed an initial ownership report for Principal Accounting Officer Austin Charette. The filing shows beneficial ownership of 40 shares of MiNK Therapeutics common stock held directly, with no specific buy or sell transaction reported.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Charette Austin

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/13/2026

3. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	40	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Austin Charette	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the MiNK Therapeutics (INKT) Form 3 for Austin Charette show?

The Form 3 reports initial ownership of common stock. It lists Principal Accounting Officer Austin Charette as directly holding 40 shares of MiNK Therapeutics, Inc. common stock, establishing a baseline of his beneficial ownership as an officer of the company.

How many MiNK Therapeutics (INKT) shares does Austin Charette report on Form 3?

The filing reports ownership of 40 common shares. The Form 3 states that after the reported entry, Austin Charette beneficially owns 40.0000 shares of MiNK Therapeutics, Inc. common stock, held directly, with no additional derivative securities listed.

Is the MiNK Therapeutics (INKT) Form 3 a buy or sell transaction?

The Form 3 is an initial ownership statement, not a trade. It records that Austin Charette, Principal Accounting Officer, holds 40 shares of common stock. No purchase, sale, or other transaction amount or price is reported in this filing.

What position does the reporting person on MiNK Therapeutics (INKT) Form 3 hold?

The reporting person is an officer of the company. The Form 3 identifies Austin Charette as an officer of MiNK Therapeutics, Inc., serving as Principal Accounting Officer, and discloses his direct beneficial ownership of 40 common shares.

Does the MiNK Therapeutics (INKT) Form 3 include derivative securities for Austin Charette?

No derivative holdings are listed for the reporting officer. The filing only shows direct ownership of 40 shares of common stock, and the derivative securities summary is empty, indicating no reportable option or other derivative positions in this Form 3.